Before US regulatory approval, an expanded access program provided plerixafor to patients with non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HD) or multiple myeloma (MM) who had not previously failed mobilization and were otherwise candidates for auto-SCT. Patients received granulocyte-CSF (G-CSF) 10 mcg/kg daily and plerixafor 0.24 mg/kg starting on day 4 with apheresis on day 5; all repeated daily until collection was complete. Overall, 104 patients received X1 dose of plerixafor. The addition of plerixafor to G-CSF resulted in a median threefold increase in peripheral blood CD34 þ cell count between days 4 and 5. Among 43 NHL patients, 74% met the target of X5 Â 10 6 CD34 þ cells/kg (median, 1 day apheresis, range 1-5 days); among 7 HD patients, 57% met the target of X5 Â 10 6 CD34 þ cells/kg (median, 2 days apheresis, range 1-3); and among 54 MM patients, 89% met the target of X6 Â 10 6 CD34 þ cells/kg (median, 1 day apheresis, range 1-4). Overall, 93% of patients had X2 Â 10 6 CD34 þ cells/kg collected within 1-3 days. Plerixafor-related toxicities were minimal. Engraftment kinetics, graft durability and transplant outcomes demonstrated no unexpected outcomes. Efficacy and safety results were similar to results in phase II and III clinical trials.
INTRODUCTION
High-dose chemotherapy and autologous hematopoietic SCT (HSCT) are integral to the treatment of patients with multiple myeloma (MM), relapsed Hodgkin's lymphoma (HD) and non-Hodgkin's lymphoma (NHL). [1] [2] [3] Mobilization of hematopoietic stem cells (HSC) into the peripheral blood (PB) using chemotherapy and/or cytokines followed by apheresis is the most common method used by many centers for autologous HSC collection. [4] [5] [6] Plerixafor is a CXCR4 (C-X-C chemokine receptor type 4) antagonist that disrupts the SDF-1 (stromal cell-derived factor 1)/CXCR4 interaction and reduces the binding and chemotaxis of HSCs to the BM stroma. Plerixafor in combination with granulocyte-CSF (G-CSF) is now FDA (Food and Drug Administration) approved to mobilize HSCs to the PB for collection and subsequent autologous transplantation in patients with NHL and MM. This indication is based on two phase III, double-blind, randomized clinical studies that demonstrated that the combination of G-CSF and plerixafor mobilizes more HSC in fewer apheresis sessions compared with G-CSF alone in MM and NHL patients. 7, 8 An expanded access program (EAP) was initiated after the phase III studies were complete but before FDA approval of plerixafor. The primary objective of this EAP was to provide access to plerixafor for patients with NHL, HD and MM who were otherwise candidates for autologous HSCT. This program also provided an opportunity to add additional safety and efficacy data to the findings already captured in the phase II and III studies. The EAP included a database of clinical outcomes associated with plerixafor-based mobilization at multiple transplant centers. In this report, we describe the safety and efficacy results obtained from this EAP.
PATIENTS AND METHODS
The EAP was a multi-center, single arm, open-label program intended to provide expanded access to plerixafor for patients with NHL, HD or MM for whom treatment with an autologous HSCT was planned. The EAP was approved by the Institutional Review Boards at all participating centers and all patients provided written informed consent. Patients were accrued to the EAP from July 2008 through January 2009.
Patient eligibility
To be eligible for this EAP, patients had to be at least 4 weeks from previous chemotherapy and 2 weeks from previous cytokine therapy, and have o20% BM involvement with disease. Patients who had previously failed stem cell mobilization attempts or who had previously received an auto-or allo-SCT were not eligible.
Treatment
Patients were given 10 mg/kg G-CSF each morning for 4 consecutive days. PB samples were collected before the first administration of plerixafor (on day 4) and before administration of G-CSF on the first day of apheresis (on day 5) to determine the number of CD34 þ cells in the PB. Starting on the evening of day 4, plerixafor 0.24 mg/kg was administered subcutaneously and continued once daily before collection days, while G-CSF was continued each morning before apheresis. The plerixafor dose was timed to allow for a 10-11-h interval between the plerixafor dosing and the initiation of apheresis. On day 5, patients returned to the clinic and received a morning dose of G-CSF (10 mg/kg) approximately 1 h before apheresis, and this was repeated on each of the days of collection. Stem cell collection took place using standard procedures, with a recommended three blood volume apheresis.
The optimal target CD34 þ cell yield was defined as X5 Â 10 6 CD34 þ cells/kg for patients with NHL and HD or X6 Â 10 6 CD34 þ cells/kg for patients with MM. Investigators were permitted, but not required, to stop mobilization and apheresis after collecting this target number of cells. For patients for whom additional apheresis was desired or required, daily retreatment with G-CSF and plerixafor as well as daily apheresis was allowed by protocol for up to a total of five apheresis procedures. The mobilized stem cells could be used in a tandem transplant if indicated and as long as a minimum number of CD34 þ cells/kg (X2 Â 10 6 CD34 þ cells/ kg for each transplant) was available.
Following the last apheresis procedure, patients in whom a sufficient number of CD34 þ cells had been recovered underwent pre-transplant myeloablative chemotherapy followed by transplantation of the collected autologous stem cells, using the established protocols and procedures at each site. If o2 Â 10 6 CD34 þ cells/kg were collected for transplantation, the patient was discontinued from further study participation, treated at the discretion of their physicians and followed for safety. Mobilized stem cells were to be used for a single autologous transplant within 2 months and for a tandem transplant within 6 months of the last apheresis procedure. Collected cells could be retained, pooled and transplanted at a later date if the investigator first obtained approval from the sponsor.
Safety assessments
Patient safety was assessed based on clinical laboratory evaluations and monitoring of adverse events (AEs). AEs were collected throughout the study and were coded using the Medical Dictionary for Regulatory Activities (MedDRA), version 12.1. The investigators at each site graded AEs using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
Efficacy analysis
Efficacy analyses were performed on data from all patients who received at least 1 dose of plerixafor during the study. The total number of CD34 þ cells collected at the time the patient completed the last apheresis, regardless of whether or not the patient completed 5 aphereses, was used to determine whether the patient could be classified as a treatment success (at least 2 Â 10 6 CD34 þ cells/kg collected). The day of the last apheresis was used to derive each of the days-to-reach-target parameters. Patients who were terminated from the study before engraftment were classified as not having reached engraftment in the analyses.
RESULTS

Patient characteristics
A total of 106 patients were enrolled in the EAP. Two patients were discontinued from the study before receiving plerixafor and are therefore not included in the analysis. Table 1 lists patient  characteristics. Overall, 104 patients received at least one dose of plerixafor, including 43 patients with NHL, 54 with MM and 7 with HD. Among patients with NHL, 21 (49%) had diffuse large B-cell lymphoma, 12 (28%) had mantle-cell lymphoma, 5 (12%) had follicular lymphoma and 5 (12%) had other histology. The time from the original diagnosis to mobilization ranged from 3 to 278 months, with medians of 12 months for NHL, 8 months for MM and 22 months for HD. Previous therapies included lenalidomide in two patients and bendamustine in one patient. Patients were accrued at 15 different centers, with each center accruing between 1 and 25 patients, with no apparent variability in terms of reaching minimum or optimum apheresis targets (data not shown).
Mobilization outcomes
Overall, plerixafor resulted in a median threefold increase in the PB CD34 þ cell count between day 4 and day 5 ( Figure 1 ). Figure 2 shows the percentage of patients reaching the minimum and optimum CD34 þ cell collection on each day of apheresis. Of 43 patients with NHL, 32 (74%) met the target of X5 Â 10 6 CD34 þ cells/kg with a median of 1 day (range 1-5 days). Four (57%) of seven patients with HD met the target of X5 Â 10 6 CD34 þ cells/ kg with a median of 2 days (range 1-3 days). Of 54 patients with MM, 48 (89%) met the target of X6 Â 10 6 CD34 þ cells/kg with a median of 1 day (range 1-4 days) ( Table 2) . Overall, 97 (93%) of 104 patients had X2 Â 10 6 CD34 þ cells/kg collected in 1-3 days of apheresis. The median number of doses of plerixafor received by patients was 2 (range 1-5). The 7 (7%) patients who did not achieve yields of X2 Â 10 6 CD34 þ cells/kg included two patients with NHL withdrawn for AEs, one patient with NHL who collected 1.8 Â 10 6 CD34 þ cells/kg and proceeded to transplant and four patients (2 NHL, 1 HD, 1MM) who failed to collect sufficient stem cells, three of whom terminated the study early and one who completed the protocol-specified maximum of five apheresis sessions.
We performed a post hoc analysis of the subgroup of patients who collected different thresholds of CD34 þ cells/kg in the first single apheresis session stratified by the preceding day's PB CD34 þ cell/mL count (Table 3) (Table 3) . A PB CD34 þ cells counts of X20 cells/mL on day 4, before the first dose of plerixafor, corresponded with 37 of 42 (88%) of patients yielding 5 Â 10 6 /kg CD34 þ cells in the day-5 apheresis product (Table 3) .
Transplant outcomes A total of 92 patients (87%; 37 with NHL, 4 with HD and 51 with MM) underwent autologous transplantation. One patient with MM also had a second transplant. Table 4 summarizes the median time to neutrophil and platelet engraftment. One patient discontinued from the study immediately after transplantation and before engraftment was assessed. All the remaining 91 patients transplanted had successful ANC and platelet engraftment.
Engraftment status was assessed 100 days, 6 months and 12 months after transplantation. Of the 92 patients who underwent transplantation, post-transplant follow-up data were available for 87 patients (84%) at 100 days, 85 patients (82%) at 6 months and 78 patients (75%) at 12 months. All grafts were assessed as durable at all time points, with no reports of secondary graft failure (data not shown).
AEs
During mobilization, 39 (38%) patients experienced AEs. The AEs experienced by X2 patients and considered possibly related to study drug were: injection site erythema (20 patients), injection site rash (5 patients), injection site pruritus (4 patients), nausea/ vomiting or diarrhea (4 patients), fatigue (2 patients), injection site swelling (2 patients), lymphopenia (2 patients), paresthesia (2 patients) and thrombocytopenia (2 patients). One patient experienced serious AE probably or definitely related to study drug of: diarrhea (mild), fatigue (moderate), hypotension (mild), nausea (severe) and vomiting (moderate).
Three (3%) patients discontinued study treatment owing to AEs. Two patients discontinued during mobilization owing to events that were not reported as related to study drug (atrial fibrillation plus pulmonary embolism in 1 patient and progression of MM in the other). One patient discontinued owing to events that were probably related to study drug (nausea and vomiting).
Overall, nine deaths were reported among the patients enrolled in the EAP. Eight deaths were due to disease progression or relapse and were not reported as related to study drug. Death due to respiratory arrest (not related to study drug) was reported outside of the protocol-specified reporting period for one patient Mobilization outcomes of G-CSF/plerixafor P Shaughnessy et al who had withdrawn from the study and did not proceed to transplant.
DISCUSSION
The primary objective of the EAP was to provide plerixafor to transplant centers for patients who were candidates for autologous HSCT and who were undergoing a first mobilization attempt. Study patients were not necessarily predicted to be at high risk for stem cell mobilization failure and had not failed previous stem cell mobilization. Overall, 93% of patients reached or exceeded the minimum number of 2 Â 10 6 CD34 þ cells/kg for transplant. In addition, in one apheresis session, we were able to collect at least 2 Â 10 6 CD34 þ cells/kg from 80% of patients and at least 5 Â 10 6 CD34 þ cells/kg from 51% of patients (Table 3) . These findings are similar to the success rate for the combination of G-CSF and plerixafor reported in the phase III studies. 7, 8 The EAP also expands the limited experience of plerixafor with HD and demonstrates, although in small numbers, similar success rates and toxicity profiles in HD patients.
The safety profile we observed in this EAP comprised events commonly associated with mobilization, apheresis, myeloablative chemotherapy and transplant procedures. A total of 3 (3%) patients discontinued study treatment owing to AEs. One patient experienced nausea and vomiting related to study drug, and the remaining two patients experienced atrial fibrillation plus pulmonary embolism and progression of MM, which were not determined to be related to study drug. All patients with available engraftment data demonstrated engraftment of neutrophils and platelets. The time to engraftment was within the range expected in this patient population. All grafts assessed during the 12-month post-transplant follow up were durable. The eight deaths in the EAP were attributed to disease progression or relapse and were not determined to be related to study drug. The relapse rate we observed does not appear to be different to that reported in the literature; 7, 8 however, further follow up may be warranted. Overall, the AE profile from this study is similar to that seen in previously published clinical trials; 7, 8 thus further confirming the tolerability of this regimen.
In a post hoc analysis of this study, we attempted to discern if the day-4 PB CD34 þ cell count, before receiving plerixafor, was associated with the ability to achieve certain levels of CD34 þ cells in the apheresis product on day 5. Our data reveal that a day-4 PB CD34 þ cell count 410 cells/mL, before receiving plerixafor, was associated with 95% of patients yielding a minimum of 2 Â 10 6 CD34 þ cells/kg in one apheresis collection on day 5. However, to collect the optimal target of 5 Â 10 6 CD34 þ cells/kg, a threshold of X20 CD34 þ cells/mL on day 4, before plerixafor, was needed for 88% of patients to reach this target in one apheresis session.
Cost-containment concerns have led centers to adopt algorithms to use plerixafor with G-CSF only in patients who appear to be at risk of failure to yield adequate CD34 þ cells/kg based on certain pre-collection levels of PB CD34 þ cells/mL or the results of the first day of apheresis. 9, 10 Depending on the design and the level set as the minimum target of CD34 þ cells/kg, some algorithms can require multiple days of apheresis to achieve that target. A previous retrospective study, comparing plerixafor plus G-CSF (P þ G) with cyclophosphamide plus G-CSF (CM þ G), found that the cost of HSC mobilization and collection increased dramatically when multiple days of G-CSF/plerixafor and apheresis were required. 11 Although the total median mobilization costs were similar in the two groups, P þ G patients had more predictable apheresis schedules, used less resources and had fewer hospitalizations.
Recent publications have found that plerixafor is safe and efficacious when added to chemotherapy mobilization and may accelerate the rate of increase in CD34 þ cells collected, 12 as well as rescue poor mobilizers. 13 Future studies will be needed to define algorithms for using plerixafor after chemotherapy mobilization and also to assess cost and resource utilization of this approach.
Costa et al. 14 formulated an algorithm that takes into account the goal of CD34 þ cell collection as well as the number of days of apheresis desired to determine the cost effectiveness of adding plerixafor to G-CSF mobilization based on the day-4 PB CD34 þ cells/mL. To be more widely applicable, this single-center study would need to be repeated and validated at individual centers because of the many variable factors that determine the cost effectiveness of HSC mobilization and collection between institutions. The post hoc analysis in the EAP, which gathered data from multiple institutions, found that a threshold effect of the day-4 CD34 þ cells/mL before receiving plerixafor administration could be used to reliably predict collecting a target apheresis product in 1 day of apheresis. The EAP also demonstrated that if the day-4 PB CD34 þ level is below a certain threshold, multiple days of apheresis may be necessary, potentially requiring the adjustment of logistical and staffing requirements related to the apheresis center, cell therapy lab and flow cytometry, as well as patient scheduling. Similar approaches to algorithm management at single centers have been recently reported. 10, 15, 16 Individual centers may need to consider variables in how stem cells are mobilized and collected that are unique to their institutions. Larger prospective studies are needed to confirm if the increased cost associated with the use of plerixafor is offset by decreased apheresis costs. Future analyses should also assess the impact of a reduction in apheresis and cytokine use associated with plerixafor use on patient quality of life, logistical parameters and staffing requirements.
In conclusion, this EAP allowed more patients access to plerixafor for mobilization, before regulatory approval, at transplant centers with and without previous experience in the use of this agent. This program provides additional efficacy and safety data on the use of plerixafor in patients with HD, and the results we observed for patients with MM and NHL were similar to those reported in the phase III studies.
